DOCSLIB.ORG

Empirx Health 2018 Basic Plus Formulary List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

EmpiRx Health 2018 Basic Plus Formulary List The 2018 Basic Plus Formulary drug list is shown below. The formulary is the list of drugs included in your prescription drug benefit plan. Inclusion on the list does not guarantee coverage. The following list is not a complete list of over-the-counter [OTC] products and prescription medical supplies that are on the formulary. The only OTC products and prescription medical supplies that appear on the list are in contracted classes. PLEASE NOTE: Brand-name drugs may move to nonformulary status if a generic version becomes available during the year. Not all the drugs listed are covered by all prescription drug benefit programs; check your benefit materials for the specific drugs covered and the copayments for your prescription drug benefit program. For specific questions about your coverage, please call the phone number printed on your member ID card. KEY For the member: Generic medications contain the same active [INJ] – Injectable Drug ingredients as their corresponding brand-name medications, although [OTC] – Over-the-counter Product they may look different in color or shape. They have been FDA-approved [SP] – Specialty Drug under strict standards. Brand-name drugs are listed in CAPITAL letters. Example: ABILIFY For the physician: Please prescribe preferred products and allow generic Generic drugs are listed in lower-case letters. Example: ibuprofen substitutions when medically appropriate. A adapalene/benzoyl peroxide alyacen apraclonidine eye solution ADCETRIS [INJ] [SP] amabelz aprepitant abacavir [SP] ADCIRCA [SP] amantadine apri abacavir/lamivudine [SP] ADDAMEL N [INJ] AMBISOME [INJ] APTIVUS [SP] abacavir/lamivudine/zidovudine [SP] adefovir amcinonide AQUASOL A [INJ] ABELCET [INJ] ADEMPAS [SP] amethia ARALAST NP [INJ] [SP] ABILIFY MAINTENA [INJ] adenosine [INJ] amethia lo aranelle ABRAXANE [INJ] [SP] ADVAIR DISKUS amethyst ARANESP [INJ] [SP] ABSORICA ADVAIR HFA AMICAR arbinoxa acamprosate delayed-release advanced am/pm amifostine [INJ] ARCALYST [INJ] [SP] ACANYA ADVATE [INJ] [SP] amikacin [INJ] ARCAPTA NEOHALER acarbose ADYNOVATE [INJ] [SP] amiloride aripiprazole ACCU-CHEK FASTCLIX LANCETS AFINITOR [SP] amiloride/hydrochlorothiazide aripiprazole orally disintegrating tablets [OTC] AFINITOR DISPERZ [SP] amino acid [INJ] ARISTADA [INJ] ACCU-CHEK MULTICLIX LANCET KIT AFLURIA [INJ] aminocaproic acid [INJ] ARISTOSPAN [INJ] [OTC] AFLURIA QUAD [INJ] aminophylline [INJ] armodafinil ACCU-CHEK MULTICLIX LANCETS AFSTYLA [INJ][SP] AMINOSYN [INJ] ARMONAIR RESPICLICK [OTC] AKYNZEO amiodarone ARMOUR THYROID ACCU-CHEK SOFTCLIX LANCET KIT ALBENZA amiodarone [INJ] ARNUITY ELLIPTA [OTC] albumin human [INJ] AMITIZA ARRANON [INJ] [SP] ACCU-CHEK SOFTCLIX LANCETS albuterol amitriptyline ARZERRA [INJ] [SP] [OTC] albuterol ext-release amitriptyline/chlordiazepoxide ASACOL HD acebutolol albuterol nebulization solution amlodipine ascorbic acid [INJ] acetaminophen/codeine alclometasone amlodipine/atorvastatin ashlyna acetazolamide ALDURAZYME [INJ] [SP] amlodipine/benazepril ASMANEX HFA acetazolamide ext-release ALECENSA [SP] amlodipine/olmesartan ASMANEX TWISTHALER acetazolamide sodium [INJ] alendronate amlodipine/valsartan aspirin/dipyridamole ext-release acetic acid ear solution alfentanil [INJ] amlodipine/valsartan/hydrochlorothiazide atenolol acetic acid irrigation solution ALFERON N [INJ] ammonium lactate 12% topical atenolol/chlorthalidone acetic acid/aluminum acetate ear alfuzosin ext-release amoxapine ATGAM [INJ] solution ALIMTA [INJ] amoxicillin atomoxetine acetic acid/hydrocortisone ear solution ALINIA amoxicillin/potassium clavulanate atorvastatin acetic acid/oxyquinoline vaginal allopurinol amoxicillin/potassium clavulanate ext- atovaquone acetylcysteine [INJ] allopurinol sodium [INJ] release atovaquone/proguanil acetylcysteine inhalation solution almotriptan amphotericin [INJ] ATRIPLA [SP] acitretin alosetron ampicillin atropine [INJ] ACTEMRA [INJ] [SP] ALOXI [INJ] ampicillin sodium [INJ] atropine sulfate eye ointment ACTHAR H.P. [INJ] [SP] ALPHAGAN P 0.1% ampicillin sodium/sulbactam [INJ] atropine sulfate eye solution ACTHIB [INJ] ALPHANATE [INJ] [SP] AMPYRA [SP] ATROVENT HFA ACTHREL [INJ] ALPHANINE SD [INJ] [SP] AMYTAL [INJ] aubra ACTIMMUNE [INJ] [SP] alphaquin hp anagrelide AUGMENTIN 125-31.25 MG/5 ML ACTIVASE [INJ] alprazolam anastrozole AVASTIN [INJ] [SP] acyclovir alprazolam ext-release ANDRODERM AVELOX IV [INJ] acyclovir ointment alprazolam orally disintegrating tablets ANDROGEL 1.62% aviane acyclovir sodium [INJ] ALPROLIX [INJ] [SP] ANORO ELLIPTA avo cream ADACEL [INJ] alprostadil [INJ] anthralin AVONEX [INJ] [SP] ADAGEN [INJ] [SP] ALREX APLISOL [INJ] AVYCAZ [INJ] adapalene altavera APOKYN [INJ] [SP] azacitidine [INJ] [SP] EmpiRx Health Basic Plus Formulary AZACTAM-ISO-OSMOTIC DEXTROSE blisovi fe camrese chlorcyclizine/pseudoephedrine/codeine [INJ] BOOSTRIX [INJ] camrese lo chlordiazepoxide AZASITE BOSULIF [SP] CANASA chlordiazepoxide/clidinium azathioprine [SP] BOTOX [INJ] [SP] CANCIDAS [INJ] chlorhexidine gluconate azathioprine sodium [INJ] [SP] bp vit 3 candesartan chloroquine azelastine eye solution BREO ELLIPTA candesartan/hydrochlorothiazide chlorothiazide azelastine nasal spray BREVITAL [INJ] CAPASTAT SULFATE [INJ] chlorothiazide sodium [INJ] azithromycin briellyn capecitabine [SP] chlorpheniramine/phenylephrine/ azithromycin [INJ] BRILINTA CAPRELSA [SP] dextromethorphan aztreonam [INJ] brimonidine eye solution captopril chlorpromazine azuphen mb BRINEURA [INJ] [SP] captopril/hydrochlorothiazide chlorpromazine [INJ] azurette BRISDELLE CARAC chlorthalidone bromfenac eye solution CARAFATE SUSPENSION chlorzoxazone B bromocriptine carbachol [INJ] CHOLBAM [SP] bacitracin [INJ] brompheniramine/pseudoephedrine/ CARBAGLU [SP] cholestyramine bacitracin eye ointment codeine carbamazepine cholestyramine light bacitracin/polymyxin eye ointment brompheniramine/pseudoephedrine/ carbamazepine ext-release choline salicylate/magnesium salicylate baclofen dextromethorphan carbidopa CHORIONIC GONADOTROPIN [INJ] BAL IN OIL [INJ] budesonide ext-release carbidopa/levodopa [SP] balanced salt eye irrigation solution budesonide nebulization suspension carbidopa/levodopa ext-release chromium chloride [INJ] bal-care dha prenatal vitamins bumetanide carbidopa/levodopa orally disintegrating CIALIS balsalazide bumetanide [INJ] tablets ciclopirox balziva bupivacaine [INJ] carbidopa/levodopa/entacapone ciclopirox shampoo BANZEL bupivacaine/dextrose [INJ] carbinoxamine cidofovir [INJ] BARACLUDE SOLUTION bupivacaine/epinephrine [INJ] carboplatin [INJ] ciferex BAVENCIO [INJ] [SP] buprenorphine carteolol eye solution cilostazol b-complex [INJ] buprenorphine [INJ] carvedilol cimetidine BEBULIN [INJ] [SP] buprenorphine/naloxone caspofungin [INJ] CINRYZE [INJ] [SP] bekyree bupropion CATHFLO ACTIVASE [INJ] CIPRODEX benazepril bupropion ext-release CAVERJECT [INJ] ciprofloxacin benazepril/hydrochlorothiazide bupropion ext-release (smoking CAYSTON [SP] ciprofloxacin ear solution BENDEKA [INJ] [SP] deterrent) caziant ciprofloxacin ext-release BENEFIX [INJ] [SP] buspirone cefaclor ciprofloxacin eye solution BENLYSTA [INJ] [SP] busulfan [INJ] cefaclor ext-release ciprofloxacin lactate [INJ] benoxinate/fluorescein eye solution butalbital/acetaminophen cefadroxil ciprofloxacin lactate/dextrose [INJ] benzonatate butalbital/acetaminophen/caffeine cefazolin [INJ] cisplatin [INJ] benzoyl peroxide butalbital/acetaminophen/caffeine/ cefdinir citalopram benzphetamine codeine cefditoren citric acid/sodium citrate benztropine butalbital/aspirin/caffeine cefepime [INJ] cladribine [INJ] benztropine [INJ] butalbital/aspirin/caffeine/codeine cefepime/dextrose [INJ] clarithromycin BEPREVE butorphanol [INJ] cefixime clarithromycin ext-release BERINERT [INJ] [SP] butorphanol nasal cefotaxime [INJ] clemastine BESPONSA [INJ] [SP] BUTRANS cefotetan [INJ] clindamycin hcl betamethasone acetate/betamethasone BYDUREON [INJ] cefoxitin [INJ] clindamycin palmitate sodium phosphate [INJ] BYETTA [INJ] cefoxitin/dextrose [INJ] clindamycin phosphate [INJ] betamethasone dipropionate BYSTOLIC cefpodoxime clindamycin phosphate topical betamethasone dipropionate augmented BYVALSON cefprozil clindamycin phosphate vaginal ceftazidime [INJ] clindamycin phosphate/benzoyl peroxide betamethasone valerate C BETASERON [INJ] [SP] CEFTAZIDIME/DEXTROSE [INJ] clindamycin phosphate/dextrose [INJ] betaxolol cabergoline ceftibuten clindamycin phosphate/tretinoin betaxolol eye solution CABOMETYX [SP] ceftriaxone [INJ] CLINIMIX [INJ] bethanechol caffeine citrated ceftriaxone/dextrose [INJ] CLINIMIX E [INJ] BETHKIS [SP] caffeine citrated [INJ] cefuroxime axetil clobetasol propionate BEVESPI AEROSPHERE caffeine/sodium benzoate [INJ] cefuroxime sodium [INJ] clobetasol propionate shampoo bexarotene [SP] calcipotriene celacyn clobetasol propionate/emollient BEXSERO [INJ] calcipotriene/betamethasone celecoxib clofarabine [INJ] bicalutamide dipropionate CELONTIN clomiphene citrate BICILLIN C-R [INJ] calcitonin salmon nasal centratex clomipramine BICILLIN L-A [INJ] calcitriol cephalexin clonazepam BICNU [INJ] calcitriol [INJ] CEPROTIN [INJ] [SP] clonazepam orally disintegrating tablets BILTRICIDE calcitriol ointment CERDELGA [SP] clonidine bimatoprost eye solution calcium acetate CEREZYME [INJ] [SP] clonidine [INJ] BIOTHRAX [INJ] calcium chloride [INJ] cetirizine syrup clonidine ext-release bisoprolol CALCIUM DISODIUM VERSENATE CETROTIDE [INJ] [SP] clonidine patches bisoprolol/hydrochlorothiazide [INJ] cevimeline clonidine/chlorthalidone bivalirudin [INJ] calcium gluconate
Recommended publications
  • PROZAC Product Monograph Page 1 of 49 Table of Contents

    PROZAC Product Monograph Page 1 of 49 Table of Contents

    PRODUCT MONOGRAPH PrPROZAC® fluoxetine hydrochloride 10 mg and 20 mg Capsules Antidepressant / Antiobsessional / Antibulimic © Eli Lilly Canada Inc. Date of Revision: January, 25 Exchange Tower 2021 130 King Street West, Suite 900 PO Box 73 Toronto, Ontario M5X 1B1 1-888-545-5972 www.lilly.ca Submission Control No: 192639 PROZAC Product Monograph Page 1 of 49 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .......................................................3 SUMMARY PRODUCT INFORMATION...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS .....................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................5 ADVERSE REACTIONS ...................................................................................................13 DRUG INTERACTIONS....................................................................................................22 DOSAGE AND ADMINISTRATION ................................................................................27 OVERDOSAGE..................................................................................................................28 ACTION AND CLINICAL PHARMACOLOGY ...............................................................30 STORAGE AND STABILITY............................................................................................32
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
  • Clinical Policy: Topical Agents: Corticosteroids

    Clinical Policy: Topical Agents: Corticosteroids

    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
  • Orange Book Cumulative Supplement 7 July 2006

    Orange Book Cumulative Supplement 7 July 2006

    CUMULATIVE SUPPLEMENT 07 July 2006 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Generic Drugs 2006 Prepared By Office of Generic Drugs Center for Drug Evaluation and Research Food and Drug Administration APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Cumulative Supplement 07 July 2006 CONTENTS PAGE 1.0 INTRODUCTION ........................................................................................................................................ iii 1.1 How to use the Cumulative Supplement ........................................................................................... iii 1.2 Applicant Name Changes.................................................................................................................. iv 1.3 Availability of the Edition ................................................................................................................... vi 1.4 Report of Counts for the Prescription Drug Product List ................................................................... vi 1.5 Zocor (simvastatin) Patent Relisting.................................................................................................viii 1.6 Cumulative Supplement Legend ....................................................................................................... vi DRUG PRODUCT LISTS Prescription Drug Product List ......................................................................................................
  • Steroids Topical

    Steroids Topical

    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Psorcon®(Diflorasone Diacetate Cream, USP)

    Psorcon®(Diflorasone Diacetate Cream, USP)

    PSORCON- diflorasone diacetate cream Taro Pharmaceuticals U.S.A., Inc. ---------- psorcon® (diflorasone diacetate cream, USP) 0.05% Rx only For External Use Only - Not for Ophthalmic Use. DESCRIPTION PSORCON® (diflorasone diacetate cream USP), 0.05% contains the active compound diflorasone diacetate, a synthetic corticosteroid for topical dermatological use. Chemically, diflorasone diacetate is 6α, 9α-difluoro-11β,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17,21 diacetate, with the empirical formula C26H32F2O7, a molecular weight of 494.5, and the following structural formula: Each gram of PSORCON® (diflorasone diacetate cream USP), 0.05% contains 0.5 mg diflorasone diacetate in a cream base consisting of butylated hydroxytoluene, cetyl alcohol, citric acid, glyceryl stearate/PEG 100 stearate, isopropyl myristate, lanolin alcohol, mineral oil, monobasic sodium phosphate, polyoxyl 40 stearate, polysorbate 60, propylene glycol, purified water, sorbitan monostearate and vegetable oil. CLINICAL PHARMACOLOGY Like other topical corticosteroids, diflorasone diacetate has anti-inflammatory, anti-pruritic, and vasoconstrictive actions. The mechanism of the anti-inflammatory activity of the topical corticosteroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration.
  • Pharmacy J-Code Billing/Topical Corticosteroid

    Pharmacy J-Code Billing/Topical Corticosteroid

    Pharmacy Services (800) 522-0114, option 4 October 14, 2019 RE: Pharmacy J-Code Billing, Topical Corticosteroid Update Dear SoonerCare Provider, The purpose of this fax is to provide reminders regarding pharmacy J-code (HCPCS) billing and updates regarding coverage of topical corticosteroids (TCS). Pharmacies cannot process HCPCS codes for reimbursement through SoonerCare. Pharmacies may submit claims for drug products with a National Drug Code (NDC) for reimbursement via a pharmacy claim. Claims for medications billed by a pharmacy on a CMS1500 for HCPCS codes or J-codes will not process through the SoonerCare claims systems. Effective November 12, 2019, the following changes will apply for the TCS medications category: . Temovate® (clobetasol propionate 0.05% ointment) will move from Tier-3 to Tier-1. Prior authorization will no longer be required. Diprosone® (betamethasone dipropionate 0.05% ointment) and Trianex® (triamcinolone acetonide 0.05% ointment) will move from Tier-1 to Tier-2. Apexicon® (diflorasone diacetate 0.05% cream and ointment) and Apexicon E® (diflorasone diacetate/emollient 0.05% cream) will move from Tier-2 to Tier-3. Current users will not be “grandfathered”. All members receiving these medications will require that a manual prior authorization be submitted by their prescriber. Specific prior authorization criteria and Tier charts for TCS medications can be downloaded from www.okhca.org/pa, then clicking “Topical”. If a member requires any of the above medications, prior authorization requests can be submitted for consideration to SoonerCare Pharmacy Services. Prior authorization request forms can be found online at www.okhca.org/rxforms (PHARM-04). Thank you for the services you provide to Oklahomans insured by SoonerCare! SoonerCare Pharmacy Services • Pharmacy Management Consultants • PO Box 26901; ORI W-4403• Oklahoma City, Oklahoma 73126-0901 • Phone: (800) 522-0114, option 4 • Fax: (800) 224-4014 .
  • Drug Repurposing for the Management of Depression: Where Do We Stand Currently?

    Drug Repurposing for the Management of Depression: Where Do We Stand Currently?

    life Review Drug Repurposing for the Management of Depression: Where Do We Stand Currently? Hosna Mohammad Sadeghi 1,†, Ida Adeli 1,† , Taraneh Mousavi 1,2, Marzieh Daniali 1,2, Shekoufeh Nikfar 3,4,5 and Mohammad Abdollahi 1,2,* 1 Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran; [email protected] (H.M.S.); [email protected] (I.A.); [email protected] (T.M.); [email protected] (M.D.) 2 Department of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran 3 Personalized Medicine Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran 1417614411, Iran; [email protected] 4 Pharmaceutical Sciences Research Center (PSRC) and the Pharmaceutical Management and Economics Research Center (PMERC), Evidence-Based Evaluation of Cost-Effectiveness and Clinical Outcomes Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran 1417614411, Iran 5 Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran * Correspondence: [email protected] † Equally contributed as first authors. Citation: Mohammad Sadeghi, H.; Abstract: A slow rate of new drug discovery and higher costs of new drug development attracted Adeli, I.; Mousavi, T.; Daniali, M.; the attention of scientists and physicians for the repurposing and repositioning of old medications. Nikfar, S.; Abdollahi, M. Drug Experimental studies and off-label use of drugs have helped drive data for further studies of ap- Repurposing for the Management of proving these medications.
  • Pharmaceuticals Appendix

    Pharmaceuticals Appendix

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.